May 6, 2020 / 6:53 AM / 19 days ago

BRIEF-Novo Nordisk CFO Says Sales Of Its Obesity Drugs Impacted The Most By Coronavirus

May 6 (Reuters) - Novo Nordisk:

* CEO SAYS DURING THE PERIOD OF SOCIAL DISTANCING FEWER NEW PATIENTS ARE EXPECTED TO INITIATE TREATMENT

* CEO SAYS ALL MANUFACTURING SITES CONTINUE TO OPERATE

* CEO SAYS THE EARLY UPTAKE OF ITS ORAL DIABETES DRUG RYBELSUS WAS ENCOURAGING IN THE U.S. PRIOR TO COVID-19

* CFO SAYS HIGHER STOCK LEVELS DUE TO THE CORONAVIRUS ARE EXPECTED TO GRADUALLY REVERSE THROUGHOUT 2020 AND 2021

* CEO SAYS CORONAVIRUS WILL STALL THE LAUNCH ACTIVITIES FOR RYBELSUS FOR SOME MONTHS BUT IS NOT WORRIED ABOUT THE LONG-TERM GROWTH TRAJECTORY

* CFO SAYS SALES OF ITS OBESITY DRUGS IMPACTED THE MOST BY THE CORONAVIRUS Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below